Business
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard
About this update from Nexgel, Inc
[{"type":"image","alt":"NEXGEL, INC.","displaySize":"","headline":null,"caption":"NEXGEL, INC.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":66,"url":"https://media.zenfs.com/en/globenewswire.com/7f0d3c847df57a7d87b54e7056dbb4aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ONAbP5tUr9hDfjARTjK8NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7f0d3c847df57a7d87b54e7056dbb4aa","width":250,"height":66},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ONAbP5tUr9hDfjARTjK8NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7f0d3c847df57a7d87b54e7056dbb4aa","width":250,"height":66}},"lazy":false},{"type":"text","content":"Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue","length":163,"tagName":"p"},{"type":"text","content":"LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key moment in the Company's commercial growth phase.","length":590,"tagName":"p"},{"type":"text","content":"Adam Levy, Chief Executive Officer of NEXGEL, stated, “We are excited to welcome Dave to BIONX Surgical at a pivotal time in our growth phase. He has a proven ability to build scalable sales infrastructure and establish the kind of enterprise partnerships that drive repeatable revenue. His deep expertise in biologics, combined with a proven ability to build and lead high-performing sales teams will be instrumental as we scale our commercial operations for our newly formed BIONX Surgical division.”","length":502,"tagName":"p"},{"type":"text","content":"Mr. Hazard most recently served at Nuo Therapeutics, Inc., where he spent four years successfully commercializing the Aurix wound care PRP products. During his tenure, he built a salesforce of more tha...